Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism

Cancer Research

Volumn 65, Issue 24, 2005, Pages 11429-11436

  Payne, Stacey L ^a,b   Fogelgren, Ben ^c   Hess, Angela R ^a   Seftor, Elisabeth A ^a   Wiley, Elizabeth L ^a   Fong, Sheri F T ^c   Csiszar, Katalin ^c   Hendrix, Mary J C ^a   Kirschmann, Dawn A ^a,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d CHILDREN S MEMORIAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPROPIONITRILE; FOCAL ADHESION KINASE; HYDROGEN PEROXIDE; PROTEIN LYSINE 6 OXIDASE; PROTEIN TYROSINE KINASE;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER INVASION; CATALYSIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

AMINOPROPIONITRILE; BREAST NEOPLASMS; CATALASE; CELL ADHESION; CELL MOVEMENT; ENZYME ACTIVATION; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; HYDROGEN PEROXIDE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROTEIN-LYSINE 6-OXIDASE; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 29244436384     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1274     Document Type: Article

References (42)

1. Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol 2001;70:1-32.
2. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003;88:660-72.
3. Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol 1998;16:387-98.
4. Li W, Nellaiappan K, Strassmaier T, Graham L, Thomas KM, Kagan HM. Localization and activity of lysyl oxidase within nuclei of fibrogenic cells. Proc Natl Acad Sci U S A 1997;94:12817-22.
5. Lazarus HM, Cruikshank WW, Narasimhan N, Kagan HM, Center DM. Induction of human monocyte motility by lysyl oxidase. Matrix Biol 1995;14:727-31.
6. Li W, Liu G, Chou IN, Kagan HM. Hydrogen peroxide-mediated, lysyl oxidase-dependent chemotaxis of vascular smooth muscle cells. J Cell Biochem 2000;78:550-7.
7. Nelson JM, Diegelmann RF, Cohen IK. Effect of β-aminopropionitrile and ascorbate on fibroblast migration. Proc Soc Exp Biol Med 1988;188:346-52.
8. Giampuzzi M, Oleggini R, DiDonato A. Demonstration of in vitro interaction between tumor suppressor lysyl oxidase and histones H1 and H2: definition of the regions involved. Biochim Biophys Acta 2003;1647:245-51.
9. Kirschmann DA, Seftor EA, Fong SF, et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 2002;62:4478-83.
10. Stracke ML, Liotta LA. Multi-step cascade of tumor cell metastasis. In Vivo 1992;6:309-16.
11. Manes S, Mira E, Gomez-Mouton C, Lacalle RA, Martinez C. Cells on the move: a dialogue between polarization and motility. IUBMB Life 2000;49:89-96.
12. Kaplan KB, Swedlow JR, Morgan DO, Varmus HE. c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev 1995;9:1505-17.
13. Maung K, Easty DJ, Hill SP, Bennett DC. Requirement for focal adhesion kinase in tumor cell adhesion. Oncogene 1999;18:6824-8.
14. Nada S, Yagi T, Takeda H, et al. Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell 1993;73:1125-35.
15. Abe J, Takahashi M, Ishida M, Lee JD, Berk BC. c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1. J Biol Chem 1997;272:20389-94.
16. Bae YS, Rang SW, Seo MS, et al. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 1997;272:217-21.
17. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 1994;14:1680-8.
18. Schlaepfer DD, Broome MA, Hunter T. Fibronectin-stimulated signaling from a focal adhesion kinase-c-Src complex: involvement of the Grb2, p130cas, and Nck adaptor proteins. Mol Cell Biol 1997;17:1702-13.
19. Boyd CD, Mariani TJ, Kim Y, Csiszar K. The size heterogeneity of human lysyl oxidase mRNA is due to alternate polyadenylation site and not alternate exon usage. Mol Biol Rep 1995;21:95-103.
20. Cronshaw AD, Fothergill-Gilmore LA, Hulmes DJ. The proteolytic processing site of the precursor of lysyl oxidase. Biochem J 1995;306:279-84.
21. Li PA, He Q, Cao T, et al. Up-regulation and altered distribution of lysyl oxidase in the central nervous system of mutant SOD1 transgenic mouse model of amyotrophic lateral sclerosis. Brain Res Mol Brain Res 2004;120:115-22.
22. Li W, Nugent MA, Zhao Y, et al. Lysyl oxidase oxidizes basic fibroblast growth factor and inactivates its mitogenic potential. J Cell Biochem 2003;88:152-64.
23. Nellaiappan K, Risitano A. Liu G, Nicklas G, Kagan HM. Fully processed lysyl oxidase catalyst translocates from the extracellular space into nuclei of aortic smooth muscle cells. J Cell Biochem 2000;79:576-82.
24. Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ. A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 1987;38:137-47.
25. Odero-Marah VA, Khalkhali-Ellis Z, Chunthapong J, et al. Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther 2003;2:398-403.
26. Sellak H, Franzini E, Hakim J, Pasquier C. Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable up-regulation. Blood 1994;83:2669-77.
27. American Cancer Society, Inc. Cancer facts and figures 2005. Atlanta (GA): American Cancer Society, 2005. Available from: http://www.cancer.org.
28. Mahabeleshwar GH, Kundu GC. Tyrosine kinase p561ck regulates cell motility and nuclear factor κB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IκBα following hypoxia/reoxygenation. J Biol Chem 2003;278:52598-612.
29. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
30. Vepa S, Scribner WM, Parinandi NL, English D, Garcia JG, Natarajan V. Hydrogen peroxide stimulates tyrosine phosphorylation of focal adhesion kinase in vascular endothelial cells. Am J Physiol 1999;277:L150-8.
31. Fogelgren B, Polgar N, Szauter KM, et al. Cellular fibronectin binds to lysyl oxidase with high affinity and is critical for its proteolytic activation. J Biol Chem 2005;280:24690-7.
32. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
33. Hu GF. Copper stimulates proliferation of human endothelial cells under culture. J Cell Biochem 1998;69:326-35.
34. McAuslan BR, Reilly W. Endothelial cell phagokinesis in response to specific metal ions. Exp Cell Res 1980;130:147-57.
35. Raju KS, Alessandri G, Ziehe M, Gullino PM. Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst 1982;69:1183-8.
36. Ziehe M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 1982;69:475-82.
37. Goodman VL, Brewer GJ, Merajver SD. Copper deficiency as an anti-cancer strategy. Endocr Relat Cancer 2004;11:255-63.
38. Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62:4854-9.
39. Khan MK, Miller MW, Taylor J, et al. Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 2002;4:164-70.
40. Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther 2003;2:617-22.
41. Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 2000;6:1-10.
42. Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;9:1666-72.